Raising Equity of Access to Clinical Trials Special Interest Group (REACT-SIG)

The primary objective of the REACT-SIG is to provide a national network and community for clinical trial and research professionals interested in addressing inequities in access to clinical trials.

Inclusion of diverse populations in clinical trials is a matter of justice and is essential to ensure that the evidence produced may be implemented as widely as possible.

The REACT-SIG functions are to:

  • Identify and bring together the clinical trial community who are interested in improving equity of access to clinical trials for all Australians.
  • Create a forum for the exchange of ideas and to forge collaborations relevant to broadening the capability of underserved communities to be included in clinical trial activities.
  • Develop resources relevant to promoting greater equity of access to clinical trials conducted by the investigator led trials sector.

The REACT-SIG is part of ACTA's work with the Australian Teletrial Program - find out more about this project

Membership

Membership of the REACT-SIG is open to anyone interested in working to improve equity of access to clinical trials.

Register your interest via acta@acta.au

Group Leadership

  • Chair - Prof Nik Zeps

Board Sponsors

  • Prof Christopher Reid